Northern Financial Advisors Inc Buys 988 Shares of Eli Lilly and Company (NYSE:LLY)

Northern Financial Advisors Inc lifted its position in Eli Lilly and Company (NYSE:LLY) by 66.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,483 shares of the company’s stock after acquiring an additional 988 shares during the quarter. Eli Lilly and Company makes up approximately 1.2% of Northern Financial Advisors Inc’s portfolio, making the stock its 22nd largest position. Northern Financial Advisors Inc’s holdings in Eli Lilly and Company were worth $1,447,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Lipe & Dalton bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $27,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth $36,000. Family CFO Inc purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $40,000. Finally, O Brien Wealth Partners LLC grew its position in Eli Lilly and Company by 70.5% during the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 31 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded down $3.28 on Wednesday, hitting $774.49. The company’s stock had a trading volume of 832,533 shares, compared to its average volume of 3,062,959. The company has a market capitalization of $736.08 billion, a PE ratio of 114.37, a PEG ratio of 1.45 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company has a 50-day simple moving average of $761.22 and a 200 day simple moving average of $674.88. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.62 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analyst Ratings Changes

Several analysts have commented on the stock. The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Bank of America raised their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. BMO Capital Markets upped their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.